Success Metrics

Active Trials
4(100%)

Phase Distribution

Ph phase_1
4
100%

Phase Distribution

4

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
4(100.0%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

4

trials recruiting

Total Trials

4

all time

Status Distribution
Active(4)

Detailed Status

Recruiting4

Development Timeline

Analytics

Development Status

Total Trials
4
Active
4
Success Rate
N/A
Most Advanced
Phase 1

Trials by Phase

Phase 14 (100.0%)

Trials by Status

recruiting4100%

Recent Activity

4 active trials
Showing 4 of 4
recruitingphase_1

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

NCT06121557
recruitingphase_1

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer

NCT06121570
recruitingphase_1

Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

NCT05981001
recruitingphase_1

Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer

NCT05981014

Clinical Trials (4)

Showing 4 of 4 trials
NCT06121557Phase 1

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

Recruiting
NCT06121570Phase 1

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer

Recruiting
NCT05981001Phase 1

Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer

Recruiting
NCT05981014Phase 1

Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer

Recruiting

All 4 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
4